Fig. 1 · Structure

Documents & Downloads

Bosutinib (SKI-606)

Cat. No. A10161 CAS 380843-75-4

Src inhibitor

Bosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.

In Stock

Publications for Bosutinib

1 publication citing this product

  1. Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Authentic bosutinib occupies the Abl ATP-binding pocket. Isolated-domain fluorescence assays reported KD values of ∼200 picomolar for wild-type Abl and Src, compared with ∼250 nM for Src T338I. These binding endpoints do not establish cellular potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Abl (Cell-free assay) 1 nM
Src (Cell-free assay) 1.2 nM

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 IC50 > 10 μM Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay [PMID: 16970400]
BaF3 IC50 > 20 μM Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay [PMID: 16970400]
BaF3 IC50 0.15 μM Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay [PMID: 16970400]
BaF3 IC50 0.2 μM Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay [PMID: 16970400]
BaF3 IC50 0.2 μM Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay [PMID: 16970400]
BaF3 IC50 1 μM Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay [PMID: 16970400]
BaF3 IC50 3.2 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay [PMID: 26814890]
Fibroblast IC50 100 nM Inhibition of human cSrc-vSrc fusion protein expressed in rat fibroblast cells by ELISA [PMID: 17905586]
HeLa IC50 3.85 μM Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay [PMID: 29624387]
HepG2 GI50 1.15 μM Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay [PMID: 18485715]
HepG2 IC50 3.91 μM Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay [PMID: 18485715]
HT-29 GI50 1.17 μM Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B assay [PMID: 18485715]
HT-29 IC50 3.87 μM Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B assay [PMID: 18485715]
K562 IC50 0.0043 μM Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay [PMID: 26814890]

14 records · Scroll to view more

Bosutinib (SKI-606) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Bosutinib (SKI-606) from 2 published references. In vitro models include human c-Abl kinase domain; human wild-type Abl and wild-type or T338I Src kinase domains.

Bosutinib (SKI-606) In Vitro Studies

Authentic bosutinib binding site in Abl

Biochemical assay · Human c-Abl kinase domain (residues 229–512) [1]

Bosutinib occupies the ATP-binding pocket and interacts with the M318 hinge backbone. Material identity was assessed beyond mass alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Resolution of authentic bosutinib–Abl structureX-ray resolution 2.4 Å[1]

Literature-Reported Treatment Conditions

Treatment concentration
Three-fold molar excess of bosutinib over Abl during complex preparation.
Method
Protein–ligand X-ray crystallography
Vehicle
DMSO stock; DMSO and free drug removed by buffer exchange.
Reported limits
No cellular exposure; preparation duration and salt/hydration form unspecified.
Methods and source locations

Compound reported in the paper: Bosutinib (SKI-606); Compound label in the paper: Bosutinib

Compound-level attribution only; no salt conversion or validation of an Adooq lot.

Results: Identification of a reliable commercial source; Interactions between bosutinib and Abl; Fig. 1B–C; Fig. 2A–B; Table 1; Methods: NMR and X-ray refinement

Resolution of authentic bosutinib–Abl structure: X-ray crystallography; chlorine anomalous scattering confirms aniline substitution positions. — Table 1; Fig. 1C; Results: Identification of a reliable commercial source

Bosutinib binding to Abl and Src kinase domains

Biochemical assay · Human wild-type Abl and wild-type or T338I Src kinase domains [1]

Equilibrium binding was tight for wild-type kinases and weaker for Src T338I. KD is a binding endpoint, distinct from inhibition IC50 or cellular dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Equilibrium binding to wild-type Abl and SrcKD both ∼200 picomolar[1]
Equilibrium binding to Src T338IKD ∼250 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 nM kinase domain; bosutinib titrated.
Method
Fluorescence emission at 480 nm, excitation at 280 or 350 nm.
Reported limits
Equilibration time, final titration DMSO fraction and replicate n not specified in read binding methods/captions.
Methods and source locations

Compound reported in the paper: Bosutinib (SKI-606); Compound label in the paper: Bosutinib

Compound-level attribution only; no salt conversion or validation of an Adooq lot.

Methods: Fluorescence binding assays; Results: Bosutinib becomes strongly fluorescent; Implications for activity against mutants; Fig. 1D and Fig. 2C

Equilibrium binding to wild-type Abl and Src: One-to-one equilibrium fit accounting for ligand depletion. — Results: Bosutinib becomes strongly fluorescent; Fig. 1D; Methods: Fluorescence binding assays

Equilibrium binding to Src T338I: Single-site equilibrium binding fit. — Results: Implications for activity against mutants; Fig. 2C; Methods: Fluorescence binding assays

Bosutinib (SKI-606) In Vivo Studies

In transgenic mice with inducible TGF-β signaling, continuous bosutinib administration at 2.5–10.0 mg/kg/day for 42 days reduced skin and lung collagen accumulation. Treatment accompanied fibrosis induction; reversal of established disease was not tested. [2]

Bosutinib during induction of skin and lung fibrosis

Animal study · Male TBRIcaCol1a2-Cre mice with tamoxifen-induced constitutive TGF-β receptor I signaling; n = 6 per treatment group [2]

Bosutinib reduced induced skin and lung collagen accumulation in a dose-dependent pattern. Treatment accompanied induction; reversal of established fibrosis was not tested.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Skin and lung collagen content derived from hydroxyprolineDose-response direction Dose-dependent decrease; at 10 mg/kg/day neither tissue differed significantly from uninduced control (Results).[2]

Conditions shared by the study groups

Route
Continuous delivery from subdermally implanted osmotic pump
Frequency
Continuous
Treatment course
42 days, beginning following initial tamoxifen injection
Vehicle
Methods describe saline control pumps or bosutinib pumps; detailed drug formulation unspecified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
2.5 mg/kg/day bosutinibTamoxifen-induced mice with saline pump; Fig. 2 also shows uninduced control.Reduced skin and lung collagen content compared with induced untreated group; dose-dependent pattern across doses. No exact bar heights extracted.[2]
5.0 mg/kg/day bosutinibTamoxifen-induced mice with saline pump; Fig. 2 also shows uninduced control.Reduced skin and lung collagen content compared with induced untreated group; dose-dependent pattern across doses. No exact bar heights extracted.[2]
10.0 mg/kg/day bosutinibTamoxifen-induced mice with saline pump; Fig. 2 also shows uninduced control.Reduced skin and lung collagen content compared with induced untreated group; dose-dependent pattern across doses. No exact bar heights extracted.[2]
2.5 mg/kg/day bosutinib
Model: Tamoxifen-induced male TBRIcaCol1a2-Cre mice; n = 6/group
Reported limits: Methods enumerate four induced groups; allocation of the additional uninduced Fig. 2 control is incompletely described. Age and blinding unspecified in read methods.
5.0 mg/kg/day bosutinib
Model: Tamoxifen-induced male TBRIcaCol1a2-Cre mice; n = 6/group
Reported limits: Methods enumerate four induced groups; allocation of the additional uninduced Fig. 2 control is incompletely described. Age and blinding unspecified in read methods.
10.0 mg/kg/day bosutinib
Model: Tamoxifen-induced male TBRIcaCol1a2-Cre mice; n = 6/group
Reported limits: Methods enumerate four induced groups; allocation of the additional uninduced Fig. 2 control is incompletely described. Age and blinding unspecified in read methods.
Methods and source locations

Compound reported in the paper: Bosutinib (SKI-606); Compound label in the paper: Bosutinib

Compound-level attribution only; no salt conversion or validation of an Adooq lot.

Methods: Experimental animals; hydroxyproline determination; Statistical analyses; Fig. 2A–B/caption and associated Results

Skin and lung collagen content derived from hydroxyproline: Hydroxyproline per wet tissue converted to collagen using factor 7.5. Fig. 2: μg/mg wet tissue, n = 6/group, mean +/- standard error, performed in triplicate. General Methods instead state mean ± standard deviation; reporting inconsistency retained. — Fig. 2A–B/caption; Results: Hydroxyproline content in tissues; Methods: hydroxyproline determination and Statistical analyses

2.5 mg/kg/day bosutinib · Methods: Experimental animals; Fig. 2A–B/caption; Results: Hydroxyproline content in tissues

5.0 mg/kg/day bosutinib · Methods: Experimental animals; Fig. 2A–B/caption; Results: Hydroxyproline content in tissues

10.0 mg/kg/day bosutinib · Methods: Experimental animals; Fig. 2A–B/caption; Results: Hydroxyproline content in tissues

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 380843-75-4
Applications Src inhibitor
Formula C26H29Cl2N5O3
Molecular Weight 530.4
Synonyms SKI-606
SMILES
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (175.31 mM)
Water Insoluble
Ethanol 2 mg/mL (3.77 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bosutinib (SKI-606) Research References

  1. [1] Nicholas M. Levinson, Steven G. Boxer. Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain PLOS ONE (2012). DOI: 10.1371/journal.pone.0029828 Source material
  2. [2] Peter J. Wermuth, Sergio A. Jimenez. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib) PLOS ONE (2018). DOI: 10.1371/journal.pone.0196559 Source material

Publications

1 publication citing this product

  1. Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961

Added to your cart

View Cart Checkout
Loading...